These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3220 related articles for article (PubMed ID: 32272481)

  • 1. Structure of M
    Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
    Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.
    Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI
    Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.
    Fischer A; Sellner M; Neranjan S; Smieško M; Lill MA
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel
    Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
    Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.
    Abian O; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Reyburn HT; Rizzuti B; Velazquez-Campoy A
    Int J Biol Macromol; 2020 Dec; 164():1693-1703. PubMed ID: 32745548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical screening for SARS-CoV-2 main protease inhibitors.
    Coelho C; Gallo G; Campos CB; Hardy L; Würtele M
    PLoS One; 2020; 15(10):e0240079. PubMed ID: 33022015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
    Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A
    Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
    Wang J
    J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77.
    Jiang H; Li W; Zhou X; Zhang J; Li J
    Int J Biol Macromol; 2024 Sep; 276(Pt 1):133706. PubMed ID: 38981557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
    Dai W; Zhang B; Jiang XM; Su H; Li J; Zhao Y; Xie X; Jin Z; Peng J; Liu F; Li C; Li Y; Bai F; Wang H; Cheng X; Cen X; Hu S; Yang X; Wang J; Liu X; Xiao G; Jiang H; Rao Z; Zhang LK; Xu Y; Yang H; Liu H
    Science; 2020 Jun; 368(6497):1331-1335. PubMed ID: 32321856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
    He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
    Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
    Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
    Cell Res; 2020 Aug; 30(8):678-692. PubMed ID: 32541865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 161.